| Original language | English |
|---|---|
| Pages (from-to) | 1144 |
| Number of pages | 1 |
| Journal | Pneumologie |
| Volume | 51 |
| Issue number | 12 |
| State | Published - 1997 |
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Pneumologie, Vol. 51, No. 12, 1997, p. 1144.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Results of 150 consecutive bilateral lung volume reduction procedures in patients with severe emphysema
AU - Cooper, J. D.
AU - Patterson, G. A.
AU - Sundaresan, R. S.
AU - Trulcok, E. P.
AU - Yusen, R. D.
AU - Pohl, M. S.
AU - Lefrak, S. S.
N1 - Funding Information: I close with a comment about the current lack of Medicare funding for lung volume reduction and with a question. The organizations that are the national forums for science and continuing education in thoracic surgery and in pulmonary medicine have advised HCFA that they do not consider lung volume reduction experimental. Hospital costs and professional fees therefore should be paid by Medicare when the procedure is offered to properly selected patients in centers that have track records successfully conducted, credible clinical research. There is no doubt that further research on the treatment of end-stage lung disease needs to be done and that lung volume reduction is a prime example for HCFA and the National Institutes of Health (NIH) to come together. HCFA should fund the patient care aspects of the treatment, and the NIH should support the needed research costs. Organized thoracic surgery spearheaded by the Society of Thoracic Surgeons and supported by the American Association for Thoracic Surgery and respiratory medicine have stepped forward and offered help to HCFA and the NIH in this regard. I hope that these agencies will accept this offer on behalf of patients whose dyspnea deserves palliation. I believe that a randomized study in the early 1970s to compare aortocoronary bypass to the then best available nonoperative treatment would have resulted in far quicker acceptance of the operation than occurred. We are at a similar stage with lung volume reduction, because it remains possible and perhaps likely that the benefits of lung volume reduction will prove to be transient.
PY - 1997
Y1 - 1997
UR - https://www.scopus.com/pages/publications/33748195642
M3 - Article
AN - SCOPUS:33748195642
SN - 0934-8387
VL - 51
SP - 1144
JO - Pneumologie
JF - Pneumologie
IS - 12
ER -